Abstracts

SHALL WE DANCE? EXTENDING TANGO’S RESULTS TO CLINICAL PRACTICE

Results from the TANGO study highlight the high efficacy and tolerability of lamivudine (3TC) and dolutegravir (DTG) as a switch strategy. However, trials’ populations often differ from real-practice settings. We aimed to confirm the study’s findings in our multicenter cohort. This was an observational study enrolling HIV-infected, virologically suppressed patients switching to 3TC+DTG, divided into…

EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG InSTI-BASED REGIMENS: DATA FROM REAL LIFE

Due to high efficacy and tolerability, the use of integrase strand transfer inhibitors (InSTI) is increasing not only in standard 3-drug regimens (3DR) but also in 2-drug regimens (2DR). However, few data are available about comparison of these strategies in a real-life setting. Retrospective multicentre (8 clinical centers in Italy) observational study including HIV+ treatment-experienced patients…

ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 SWITCH STUDY, TANGO

TANGO study demonstrated that switching to DTG/3TC fixed dose combination (FDC) 2-Drug Regimen (2DR) was non-inferior to continuing a TAF-based 3-drug regimen (TBR, 3DR) in maintaining virologic suppression in HIV-1 infected, ART-experienced adults through Week 48. The impact of pre-existing, HIV-1 drug resistance on virologic outcomes through Week 48 was assessed.  Participants with historical IAS…

VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS

Maintenance ART with dolutegravir (DTG)-based dual regimens (2DR) have proved their efficacy among HIV-1 infected subjects in large and randomized trials. Real-life data are scarce with limited population and follow-up. In a large cohort (Dat'AIDS), we evaluated virologic failure (VF) and resistance-associated mutations (RAMs) on DTG maintenance regimens in combination with rilpivirine (RPV) or 3TC/FTC…

CLINICAL OUTCOMES OF 2-DRUG REGIMENS (2DRS) VS 3-DRUG REGIMENS (3DRS) IN HIV

While 2DRs have shown good efficacy in clinical trials, there are limited data comparing longer term clinical outcomes to 3DRs. Antiretroviral treatment (ART) experienced persons in RESPOND starting a new 2DR or 3DR from 1/1/12-1/1/18 were included (figure). Poisson regression compared prospectively collected AIDS and non-AIDS events (non-AIDS-defining cancer, cardiovascular disease, end stage liver/renal disease,…

LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS

Chronic daily oral ART can be lifesaving but also inconvenient, increasing the risks of non-adherence and treatment failure. To address these issues, long-acting (LA) injectable regimens of the INSTI cabotegravir (CAB) and the NNRTI rilpivirine (RPV) are under evaluation. FLAIR (NCT02938520) is a randomized, Phase 3, open-label, multicenter study investigating whether switching to monthly CAB+RPV…

DTG+3TC VS DTG+TDF/FTC (GEMINI 1&2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96

In GEMINI-1&2, the dolutegravir (DTG) + lamivudine (3TC) 2-drug regimen (2DR) is non-inferior to the DTG + tenofovir/emtricitabine (TDF/FTC) 3-drug regimen (3DR) in HIV-1 ART-naïve participants at Weeks 48/96. Eleven participants on 2DR and seven on 3DR met protocol-defined Confirmed Virologic Withdrawal (CVW) criteria through Week 96. We present a detailed description of these CVWs.…

HIV-1 REPLICATION AT

The SWORD studies demonstrated non-inferiority on switch to dolutegravir (DTG) + rilpivirine (RPV) vs continuing a 3- to 4-drug Current Antiretroviral Regimen (CAR) for 48 weeks, and also showed long term suppression to HIV-1 RNA <50 c/mL. The clinical significance of low-level viral load (VL) <50c/mL remains unclear. We present here low level qualitative VL…